Skip to content

A clinical trial to study the effect of vitamin D supplementation in preventing disease relapse in patients with Inflammatory bowel disease which includes ulcerative colitis and crohns disease.

A study to assess the efficacy of vitamin D supplementation in preventing disease relapse in patients with inflammatory bowel disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010336
Enrollment
60
Registered
2017-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Inflammatory bowel disease

Interventions

Intervention1: Supplementation of Oral Cholecaliferol,Oral Calcium carbonate: Oral Cholecalciferol 60,000IU weekly once for 8 weeks,Oral Calcium carbonte 1000mg/day for one year Control Intervention1:

Sponsors

KMC Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with inactive inflammatory bowel disease between 18 to 60 years of age, presenting to department of gastroenterology during the period between January 2017 and September 2018, will be included in the study after obtaining informed consent. All patients with Crohnâ??s disease having CDAI score below 150. All patients with Ulcerative colitis who have complete mayo score below or equal to 2. All patients with 25-OH vitamin â??D concentrations less than 29ng/ml.

Exclusion criteria

Exclusion criteria: Chronic kidney disease Chronic liver disease Pregnancy Lactation Medications such as anticonvulsants, antituberculosis drugs, statins, thiazides and vitamin-D supplements and Patients with ongoing steroid therapy. All patients of Crohnâ??s disease with CDAI score above 150. All patients with Ulcerative colitis with complete mayo score above 2. All patients with 25-OH vitamin â??D concentrations more than 29ng/ml. Patients having symptomatic vitamin-D deficiency.

Design outcomes

Primary

MeasureTime frame
Disease relapseTimepoint: Over one year duration

Secondary

MeasureTime frame
Improvement in Crohns disease activity index,and complete mayo scoreTimepoint: Over one year duration

Countries

India

Contacts

Public ContactDr Raghav G N

Kasturba medical college

rgutlur@gmail.com7829243134

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026